HGV and TTV - New hepatitis viruses

Aim. To examine clinical, immunological and morphological features of HGV- and TTV-infections in patients with chronic hepatic diseases (CHD) and assess efficiency of treatment of HGV-seropositive patients. Material and methods. 202 patients with CHD were examined for markets of HBV-, HCY-, HGV- and TTV-infections. Some patients were subjected to puncture biopsy of the liver: Efficiency of interferon-alpha treatment of HGV and HBV/HCV coinfection,vas studied. Results. HGV RNA and TTV DNA were detected in 19.8 and 11.8% of cases, respectively. Biochemical indices in patients with HGV and TTV monoinfections significantly differed from those in the control group while morphological changes in most of them corresponded to those with hepatitis. INF-alpha was given to 7 patients with HCV+HBV/HCV infections. A response was achieved in 3 months in 2 of them. Conclusion. The role of HGV and TTV in hepatic diseases pathology is still unclear. Further studies on detection and examination of patients infected with G and TT vir uses are necessary. When choosing therapy, the presence of HGV RNA and TTV DNA in blood serum, virus genome in hepatocytes and histological changes in hepatic tissue should be considered.